InVitae (NVTA) Receives NYSE Non-compliance Notice

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on September 20, 2023, indicating the company is not currently in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock over a consecutive 30 trading-day period was less than $1.00 per share. The NYSE notice has no immediate effect on the listing of the common stock on the NYSE, subject to the company's compliance with the NYSE's continued listing requirements.

Invitae has notified the NYSE that it intends to bring the company into compliance with the listing standards within the required cure period.

The NYSE notification described above does not affect the company's business operations and does not conflict with or cause an event of default or acceleration under any of the company's material debt or other agreements. During the cure period, Invitae's common stock will continue to trade on the NYSE, subject to compliance with the other continued listing requirements.

You May Also Be Interested In

• Genprex signs CDMO deal to scale up diabetes gene therapy output
• Labcorp and NACHC form alliance to support community health centers
• Canadian Solar wins dismissal of Maxeon patent suit over solar tech